glp-1 for ckd agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity Renal effects of GLP-1 receptor

Contributor Information Areesha Moiz, Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital/McGill University, Montreal, QC, Canada

Excess weight, in and of itself, is not a disease. When it comes to her patients, she says, shes a stickler for a holistic approach to health, including eating a nutritious diet (not just eating less) and daily physical activity, as essential elements of the weight-loss process

Flexible Medication Formats: The ability to choose between dissolvable tablets and injections is a genuine differentiator

doi: 10.1210/jcem-24-10-1076 [DOI] [PubMed] [Google Scholar] 4

Team Kentucky is dedicated to supporting the health and well-being of Medicaid recipients who are disproportionately affected by diabetes. Kentucky has the nations sixth highest rate of diabetes, which costs the state about $5 billion annually as of 2022, according to the American Diabetes Association

Shuoker B, Pichler MJ, Jin C, Sakanaka H, Wu H, Gascuea AM, et al